Clinical trials: Temozolomide, completed
Melanoma
Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma
Temozolomide (also known as TMZ) is a chemotherapy drug given by mouth. It is similar to DTIC, the only FDA-approved chemotherapy for melanoma, but because temozolomide is given by mouth, it can be given daily over a long period…
- Trial name
- NCT00591370
- Testing
- Temozolomide (TMZ)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Uveal Melanoma, Stage III Uveal Melanoma AJCC v7
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
This randomized phase II trial studies how well cabozantinib-s-malate works compared with temozolomide or dacarbazine in treating patients with melanoma of the eye (ocular melanoma) that has spread to other parts of the body and…
- Conditions
- Recurrent Uveal Melanoma, Stage III Uveal Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7
- Trial name
- NCT01835145
- Testing
- Cabozantinib S-malate, Dacarbazine, Laboratory Biomarker Analysis
- Where
- 228 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme
Nativis Voyager for Newly Diagnosed GBM
This feasibility study will assess the effects of the Nativis Voyager therapy in patients newly diagnosed with GBM. The study will enroll and treat up to 32 subjects and will be combined with standard of care radiotherapy and…
- Trial name
- NAT109 (NCT03276286)
- Testing
- Nativis Voyager
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- Nativis, Inc.
Malignant Neoplasms of Brain
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Radiation therapy uses high-energy x-rays to kill cancer cells.
- Trial name
- ATTAC (NCT00639639)
- Testing
- tetanus toxoid, therapeutic autologous dendritic cells, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Gary Archer Ph.D.
Newly-diagnosed Glioblastoma
Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma
To assess the efficacy of an Angiotensin-II inhibitor (Losartan) to reduce peritumoral edema in newly diagnosed glioblastoma patients.
- Trial name
- ASTER (NCT01805453)
- Testing
- Losartan
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Glioblastoma
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
This clinical study will assess the doses of BKM120 appropriate for patients with newly diagnosed glioblastoma when given in combination with radiotherapy and temozolomide.
- Trial name
- NCT01473901
- Testing
- BKM120 + temozolomide, BKM120 +temozolomide with/without radiotherapy
- Where
- 8 sites in United States, Australia and 2 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Brain Tumor
Electronic Medical Record Review in Monitoring the Effects of Adherence on Myelosuppression and Morbidity in Patients With Newly Diagnosed Brain Tumors Receiving Temozolomide and Radiation Therapy
This research trial studies electronic medical record review in monitoring the effects of adherence on myelosuppression and morbidity in patients with newly diagnosed brain tumors receiving temozolomide and radiation therapy.
- Trial name
- NCT02208336
- Testing
- medical chart review
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Wake Forest University Health Sciences
Glioma
Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
The main purpose of this study is to assess the effect of a two-week pre-surgery treatment with low-dose temozolomide (TMZ) on brain tumor methylguanine-DNA (deoxyribonucleic acid) methyltransferase (MGMT) activity in patients…
- Trial name
- NCT00424554
- Testing
- temozolomide
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Leukemia
Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00083070
- Testing
- temozolomide
- Where
- 16 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Children's Oncology Group
IDH1 Mutation, IDH2 Mutation
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
This phase I/II trial studies the side effects and how well BGB-290 and temozolomide work in treating patients with gliomas (brain tumors) with IDH1/2 mutations that have come back.
- Conditions
- IDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma
- Trial name
- NCT03914742
- Testing
- PARP Inhibitor BGB-290, Temozolomide, Therapeutic Conventional Surgery
- Where
- 12 sites in United States
- Volunteers
- 67 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Soft Tissue Sarcoma, Mesothelioma
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
The purpose of this study is to determine safety and toxicity for the combination of Temozolomide and Azacitidine in the treatment of Advanced Soft Tissue Sarcoma or Malignant Mesothelioma.
- Trial name
- NCT00629343
- Testing
- Azacitidine, Temozolomide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Columbia University
Neuroblastoma, Medulloblastoma
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
The purpose of this research study is to evaluate a new investigational drug (TPI 287) for neuroblastoma and medulloblastoma both alone and in combination with temozolomide (a currently approved drug).
- Conditions
- Neuroblastoma, Medulloblastoma, Relapse
- Trial name
- NCT00867568
- Testing
- TPI 287
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Giselle Sholler
Brain and Central Nervous System Tumors
Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide
Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing…
- Trial name
- NCT00990652
- Testing
- Bortezomib, Temozolomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Nausea, Vomiting
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Patients diagnosed with malignant glioma who are receiving temozolomide will be accrued in this open label, phase 2, randomized single institution trial of aprepitant in combination with ondansetron versus ondansetron alone for…
- Conditions
- Nausea, Vomiting, Glioma
- Trial name
- NCT01450826
- Testing
- aprepitant, ondansetron
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Katy Peters
Glioblastoma, Gliosarcoma
Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
This pilot clinical trial studies the side effects of spectroscopic magnetic resonance imaging (MRI)-guided radiation therapy and how well it works in treating patients with newly-diagnosed glioblastoma or gliosarcoma.
- Trial name
- NCT03137888
- Testing
- Dose-Escalated Radiation Therapy, Spectroscopic Magnetic Resonance Imaging, Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Desmoplastic Small Round Cell Tumor, Rhabdomyosarcoma
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
The purpose of this study is to test whether the study drug prexasertib is a safe and effective treatment for people with DSRCT or RMS when given in combination with the standard drugs irinotecan and temozolomide.
- Trial name
- NCT04095221
- Testing
- Prexasertib, Irinotecan
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Glioblastoma Multiforme
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
The purpose of this study is to evaluate the anti-tumor activity and safety of Panzem NCD given in combination with daily oral fixed-dose temozolomide in patients with recurrent glioblastoma multiforme.
- Trial name
- NCT00481455
- Testing
- Panzem NCD, Temozolomide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- CASI pharmaceuticals, Inc.
Brain and Central Nervous System Tumors
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00114140
- Testing
- Temozolomide, Radiation therapy
- Where
- 47 sites in United States, Canada
- Volunteers
- 136 people
- Sponsor
- Radiation Therapy Oncology Group
Malignant Neoplasms of Brain
Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- ZAP IT (NCT00626015)
- Testing
- PEP-3-KLH conjugate vaccine, daclizumab, temozolomide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- John Sampson
Brain and Central Nervous System Tumors
Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00028795
- Testing
- temozolomide, adjuvant therapy, radiation therapy
- Where
- 230 sites in United States, Australia and 5 more
- Volunteers
- 170 people
- Sponsor
- Children's Oncology Group